Joenja
Joenja ingredients
| Active ingredient | Strength |
|---|---|
| Leniolisib Phosphate | 40 mg/1, 70 mg/1, 50 mg/1 |
What Joenja is used for
The FDA lists the approved uses on the official label (below). In the EU, leniolisib is approved as Joenja for:
Joenja is indicated for the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS) in adults and adolescents 12 years of age and older and weighing 45 kg or more.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Joenja
- Generic name
- Leniolisib
- Made by
- Pharming Healthcare Inc.
- Forms
- Tablet, Film Coated
- Given
- Oral
- Drug class
- Kinase Inhibitor
- FDA approval
- New drug application (NDA) NDA217759
- On the US market since
- 2023
Official information
- MedlinePlus drug information (search for Leniolisib)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Joenja?
Joenja (Leniolisib) is a cancer medicine made by Pharming Healthcare Inc., approved by the US FDA.
What are the ingredients of Joenja?
Joenja contains Leniolisib Phosphate (40 mg/1, 70 mg/1, 50 mg/1).
Is Joenja approved in Europe?
The same active substance is approved in the EU as Joenja.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA